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Abstract 
Purpose: To compare image-guided adaptive interstitial brachytherapy (BT) and intensity-modulated arc therapy 
(IMAT) with conventional treatment techniques in cervical cancer using an alternative biological dose summation method. 
Material and methods: Initially, 21 interstitial BT and IMAT plans of patients with cervical cancer were included 
and additional plans were created (inverse optimized interstitial, optimized intracavitary, non-optimized intracavitary 
BT plans, and conformal external beam radiotherapy [EBRT]). The most exposed volume of critical organs in BT were 
identified manually on EBRT CT images. Biological total doses (EQD2) were calculated and compared between each 
combination of BT and EBRT plans. This method was compared with uniform dose conception (UDC) in IMAT and 
conformal EBRT plans. 
Results: The D90 of high-risk CTV and D2 of bladder and sigmoid were different in BT techniques only: p = 0.0149, 
< 0.001, < 0.001, respectively. The most advantageous values were obtained in the interstitial treatment plans and in-
verse optimized interstitial plans did not differ dosimetrically from these, while optimized intracavitary plans resulted 
in worse dose-volume parameters, and the worst of all were intracavitary plans without optimization. The D2 of rec-
tum was significantly lower with IMAT than with conformal EBRT plans (p = 0.037) and showed the same trend in BT 
plans as the other parameters (p < 0.001). The UDC dose summation method overestimated D2 of bladder, rectum, and 
sigmoid (p < 0.001 for all). 
Conclusions: Although optimization improves the quality of conventional BT plans, interstitial plans produce sig-
nificantly higher dose coverage of high-risk clinical target volume (HR-CTV) and lower doses to organs at risk (OARs). 
IMAT plans decrease the dose to the rectum. UDC overestimates OARs doses. 
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Purpose 
The standard of care in the curative treatment of local-
ly advanced cervical cancer (stages IB2-IVA) are external 
beam radiotherapy (EBRT) and intracavitary (ic.) or in-
terstitial (is.) brachytherapy (BT) boost with concomitant 
chemotherapy. Both radiotherapy modalities have devel-
oped rapidly, with increasing sophisticated techniques 
appearing to escalate the dose to the tumor and spare or-
gans at risk (OARs). These include intensity-modulated 
arc therapy (IMAT) [1] and image-guided adaptive inter-
stitial brachytherapy (IGABT) [2,3]. In this situation, an 
accurate and reliable dose reporting is essential. 
The use of BT boost has been linked with pelvic con-
trol and overall survival [4]. Adaptive, conformal BT ap-
proaches result in further improved clinical outcomes [5], 
with dose coverage of the target volume (D90, the mini-
mum dose delivered to 90% of the high-risk clinical target 
volume [HR-CTV]) correlating with local tumor control 
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[2,6,7], and the minimal dose of the most exposed 2 cc of 
the OARs with normal tissue toxicity [8,9]. 
To report these dose-volume parameters properly, 
overall volumetric doses have to be integrated with EBRT 
and BT. As simple physical dose summation does not 
take into consideration the different biological effects, the 
equivalent dose given in 2 Gy fractions (EQD2) has to be 
calculated [10,11]. In the GEC-ESTRO recommendations, 
based on the EMBRACE study [12], the dose distribution 
of the EBRT is assumed to be completely uniform for 
the target volume and OARs (uniform dose conception 
– UDC) [13]. However, the EBRT dose is not always uni-
formly distributed. In the intensity-modulated radiother-
apy (IMRT) technique, the most exposed 2 cc of the OARs 
is not a disjunct volume, since its voxels are dispersed 
in the organ, as we showed earlier [14]. In previous in-
vestigations, authors added BT and EBRT dose-volume 
histogram (DVH) of EQD2 doses [15] or made rigid im-
age registration of BT and EBRT CT or MR images [16]. 
It was also shown before that the most exposed part of 
the OARs in the integrated plans evolves in the region 
where the maximum dose is in BT. However, this 2 cc is 
not in the same location as the most exposed part of EBRT 
[14]. Therefore, the simple DVH addition method sums 
the dose of two different 2 cc volumes. The rigid image 
registration technique does not take into account the de-
formation of the regions of interest and from this, doses 
of different tissues are summarized. Only deformable 
image registration (DIR) could be an appropriate method 
to integrate BT and EBRT doses for HR-CTV and OARs, 
but “currently no DIR program is capable of tracking the 
location and dose-exposure history of relevant biological 
structures within the target volumes and OARs” (ICRU 
report 89) [17]. The main problem is a foreign body (an 
applicator) in situ, which is not present on EBRT image 
data sets. 
The aim of the present study is to present an alter-
native method for adding the biologically effective doses 
of EBRT and BT in the absence of adequate deformable 
registration algorithms and compare it to the recent UDC 
method. Using biological dose summation of the most ex-
posed volumes of the critical organs, we compared IMAT 
and interstitial IGABT versus conventional treatment 
techniques in cervix cancer. 
Material and methods 
At our Institute, 21 interstitial IGABT and IMAT 
plans of patients with cervical cancer were included in 
this study. Selection criteria was stage IB2-IVA with poor 
response to EBRT. Patients were examined with pel-
vic magnetic resonance imaging (MRI) and staged with 
computed tomography (CT) or positron emission tomog-
raphy-computed tomography (PET-CT) at the beginning, 
and the therapeutic effect was assessed with an MRI at 
the end of EBRT. The EBRT was delivered with an ener-
gy of 10 MV using 2 full arcs. The prescribed dose was 
1.8/50.4 Gy for the whole pelvis. Based on our local IGRT 
protocol, CBCT verification was made from 1st to 3rd frac-
tions; the systematic error was calculated and corrected 
before the 4th fraction and weekly verification was com-
pleted for patient positioning. EBRT was complemented 
with BT boost, delivered with combined interstitial-in-
tracavitary technique, starting 1 week after EBRT, given 
1 or 2 fractions weekly. Because of a given EBRT boost or 
due to a weak condition, thirteen patients were treated 
with 4 BT fractions of 7 Gy, five with 3, two with 2, and 
one with 1 fraction. Initial and post- EBRT MRI were used 
to determine the number and position of needles in the 
ring or Fletcher type interstitial applicator [18,19,20]. The 
implantation was transrectal US-guided. The delineation 
of HR-CTV of bladder, rectum, sigmoid, and bowel was 
performed on post-implant CT, using information of 
post-EBRT MRI. During treatment planning, manual op-
timization (MO) was used to achieve an optimal dose dis-
tribution. In clinical routine, the EUD method was used 
to determine the dose constraints for HR-CTV and OARs 
in remaining BT fractions. The total doses were also cal-
culated with this method [21,22]. 
Besides manual optimized interstitial (MOIS) and 
IMAT treatment plans, additional BT and EBRT plans 
were created: 
• In inverse optimized interstitial BT plans (IOIS), only 
the HIPO (hybrid inverse planning optimization) 
dose-volume-based algorithm was used. The weight 
of different DVH constraints (cost functions) was 
tuned to achieve optimal dose distribution; 
• Manual optimized intracavitary BT plans (MOIC) 
were 3D optimized (based on CT), but without us-
ing the needles. Dose was prescribed to points A and 
manual optimization was used; 
• Non-optimized intracavitary BT plans (NOIC) dosim-
etry was based on points A without optimization; 
• Conformal EBRT plans (CONF) used the convention-
al 4 field box technique, with 18 MV photon beams. 
Since the most exposed part of the OARs is in the re-
gion where the maximum dose is in BT, the most exposed 
2 cc of bladder, rectum, and sigmoid were determined 
in BT CTs (Oncentra Brachy v. 4.5.3, Elekta Brachythera-
py, Veendendaal, The Netherlands). Subsequently, these 
most exposed 2 cc from BT were manually identified on 
EBRT CT images for every patient (Eclipse v. 13.7, Varian 
Medical Systems, Palo Alto, USA) (Figure 1). We inves-
tigated BT and EBRT CT image sets on the same moni-
tor in axial, sagittal, and coronal views, and delineated 
2 cc volume on EBRT CT in the same anatomical place 
where the isodose surface of the dose of the most exposed 
2 cc was found in the BT CT. To reduce subjectivity, one 
BT expert physicist along with one radiation oncologist 
(experienced in gynecologic BT) performed this critical 
part of the investigation. 
The total EQD2 doses of these volumes were calcu-
lated in each combination of BT and EBRT plans using 
the linear-quadratic radiobiological model. The α/β of 
HR-CTV was assumed 10 Gy, while for OARs, 3 Gy was 
used. The following dose-volume parameters were used 
for quantitative evaluation of plans: 
• D90: the minimum dose delivered to 90% of HR-CTV 
(Gy); 
• D2(x): the minimal dose of the most exposed 2 cc of 
the critical organ x (Gy), 
where x is the bladder (b), rectum (r), or sigmoid (s). 
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Two-way ANOVA and Fisher-LSD (least significant 
difference) post-hoc tests were used (Statistica 12.5, Stat-
Soft, Tulsa, OK, USA) to compare biological total dose of 
different treatment combinations: 
• IMAT EBRT + MOIS BT, 
 + IOIS BT, 
 + MOIC BT, 
 + NOIC BT; 
• CONF EBRT + MOIS BT, 
 + IOIS BT, 
 + MOIC BT, 
 + NOIC BT. 
This dose summation method was compared with 
UDC in combined MOIS BT plans and IMAT, or confor-
mal EBRT plans using Wilcoxon-matched pairs test. 
Results 
The mean volume of the HR-CTV after EBRT (residu-
al tumor volume) was 46.1 cc (range, 24.1-100.2 cc). Com-
paring different combinations of BT and EBRT plans, we 
found that D90 of high-risk CTV and D2 of bladder and 
sigmoid were different in BT techniques only: p = 0.0149, 
< 0.001, < 0.001, respectively. The most advantageous val-
ues were obtained in the MOIS plans. IOIS plans did not 
differ dosimetrically from these plans, while MOIC plans 
resulted in worse dose-volume parameters, and the worst 
of all were NOIC plans (Table 1). The D2 of rectum was 
significantly lower with IMAT than with CONF EBRT 
plans (p = 0.037) and showed the same trend in BT plans 
as the other parameters (p < 0.001). D2(r) were 40.0 Gy, 
38.4 Gy, 44.9 Gy, and 72.1 Gy for IMAT and MOIS, IOIS, 
MOIC, and NOIC combinations, respectively, and 49.0 Gy, 
47.3 Gy, 53.8 Gy, and 81.1 Gy for CONF EBRT and MOIS, 
IOIS, MOIC, and NOIC plans (Figure 2). 
The post-hoc test showed significant differences in all 
variables between is. (MOIS and IOIS) and ic. (MOIC and 
NOIC) BT plans, while D2(b) and D2(r) differed between 
MOIC and NOIC plans. 
It was found that the HR-CTV was exposed at least 
with the recommended EQD2 total dose (85 Gy) in 86% of 
the patients with the IMAT + MOIS IGABT technique. With 
the IOIS, MOIC, and NOIC plans, this was only 79%, 64%, 
and 71%, respectively. The same proportions were derived 
with CONF EBRT. In 86% of the patients, the D2 rectal dose 
was below recommended tolerance dose in MOIS BT and 
IMAT or CONF EBRT plans, while for IOIS BT plans, it was 
86% and 79%, for MOIC plans 79% and 71%, and NOIC BT 
plans only 43% and 36%, respectively (Table 1). 
Comparing our dose summation method to UDC in 
IMAT and CONF EBRT plans, we found that the UDC 
overestimates D2 of bladder by 12% and 8.5%, rectum by 
55% and 26.5% (Figure 3) and sigmoid by 17.2% and 12%, 
respectively. Detailed EQD2 and p values are presented 
in Table 2. 
Discussion 
Brachytherapy boost has a fundamental role in the 
radiotherapy of locally advanced cervical cancer [23]. 
Presently, there are no better alternatives [1,24]; however, 
several high-tech EBRT techniques are possible competi-
tors such as conformal [25], image-guided [1] and inten-
sity-modulated EBRT [26,27], arc therapy [28], helical to-
motherapy [29], and stereotactic radiotherapy with linear 
accelerators [30,31,32] or with CyberKnife [33]. 
Fig. 1. The most exposed 2 cc of bladder in BT (A) contoured in EBRT CT (B) in an axial slice
A B
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Although MRI-based BT has been considered the 
‘gold standard’ by international recommendations [13], 
in the lack of its broad availability, CT-based contouring 
and planning can also lead to similar dosimetrical and 
clinical results with the use of post-EBRT MRI [34,35,36]. 
The latter case has an advantage over MRI-based BT: im-
age registration is easier between post-implant CT and 
EBRT CT than between post-implant MRI and EBRT CT. 
At this moment, DIR is not yet available even between 
similar imaging modalities. The fundamental reasons are 
Table 1. Mean EQD2 total doses of different combinations of BT and EBRT plans
EQD2 MOIS IOIS MOIC NOIC p* (TT) p* (BT) 
D90 (HR-CTV) (Gy) IMAT 84.6 (86%) 84.3 (79%) 82.2 (64%) 88.7 (71%) 0.9899 0.0149 
CONF 84.6 (86%) 84.3 (79%) 82.2 (64%) 88.7 (71%) 
D2(b) (Gy) IMAT 62.9 (93%) 62.5 (93%) 71.5 (79%) 88.4 (36%) 0.434 < 0.001 
CONF 64.9 (93%) 64.6 (100%) 73.6 (71%) 90.5 (36%) 
D2(r) (Gy) IMAT 40.0 (86%) 38.4 (86%) 44.9 (79%) 72.1 (43%) 0.037 < 0.001 
CONF 49.0 (86%) 47.3 (79%) 53.8 (71%) 81.1 (36%) 
D2(s) (Gy) IMAT 55.3 (100%) 54.4 (100%) 60.5 (82%) 71.2 (64%) 0.2794 < 0.001 
CONF 57.9 (100%) 56.9 (100%) 63.5 (64%) 73.8 (55%) 
MOIS – manual optimized interstitial, IOIS – inverse optimized interstitial, MOIC – manual optimized intracavitary, NOIC – non-optimized intracavitary BT plans, 
IMAT – intensity-modulated arc therapy, CONF – conformal EBRT plans, D90 – the minimum dose delivered to 90% of HR-CTV, D2(b), D2(r), D2(s) – the minimal dose 
of the most exposed 2 cc of bladder, rectum, and sigmoid
In brackets: percentage of plans, which fulfilled the criteria of GEC-ESTRO Recommendation. *2-way ANOVA and Fisher-LSD post-hoc test 
 MOIS IOIS MOIC NOIC 
 IMAT EBRT          CONF EBRT
Fig. 2. Total EQD2 of the most exposed 2 cc of rectum in 
combinations of intensity-modulated arc therapy (IMAT) 
or conformal (CONF) EBRT and manual optimized inter-
stitial (MOIS), inverse optimized interstitial (IOIS), manual 
optimized intracavitary (MOIC), and non-optimized intra-
cavitary (NOIC) BT plans 
Fig. 3. Total EQD2 of the most exposed 2 cc of rectum in 
interstitial brachytherapy and intensity-modulated arc 
therapy (IMAT) or conformal (CONF) EBRT using our 
dose summation method and using uniform dose concep-
tion (UDC) 
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Table 2. The EQD2 total doses of interstitial BT plus intensity-modulated arc therapy (IMAT) or conformal 
(CONF) EBRT plans and the same parameters calculated by the UDC method
D90 (HR-CTV) (Gy) D2(b) (Gy) D2(r) (Gy) D2(s) (Gy) 
IMAT 84.6 62.9 40.0 55.3 
p* 0.6547 < 0.001 0.0012 0.0033 
CONF 84.6 64.9 49.0 57.9 
p* 0.6547 < 0.001 < 0.001 0.0081 
UDC 84.5 70.4 62.0 64.8 
D90 – the minimum dose delivered to 90% of HR-CTV, D2(b), D2(r), D2(s) – the minimal dose of the most exposed 2 cc of bladder, rectum, and sigmoid. *Wilcox-
on-matched pairs test 
Journal of Contemporary Brachytherapy (2019/volume 11/number 1)
Biological dose summation of cervix tele- and brachytherapy 73
the foreign body (plastic or metal applicator) in situ and 
the deformation of organs due to application. Other au-
thors added BT and EBRT DVHs directly [15] or used rig-
id image registration [16] instead of DIR. We mimicked 
DIR ‘in mind’ by defining the most exposed 2 cc of crit-
ical organs in BT CT, and then delineating this volume 
on EBRT CT. In this way, the addition of biological doses 
of the same volumes (2 cc) became possible without soft-
ware image registration. Obviously, this manual delinea-
tion has also limitations such as inter-observer variability. 
It is a time-consuming method, and identification of these 
2 cc volumes is not trivial with different bladder and rec-
tal filling. 
Gelover et al. [15] did not find statistically significant 
differences between EQD2 doses of OARs in conformal 
and IMRT EBRT techniques by adding EBRT and BT 
DVHs; however, they did not add the dose of the same 
volumes of OARs. In our analysis, D2 (EQD2) of the 
rectum was significantly lower by 9 Gy (on average) in 
IMAT than in CONF EBRT plans. This may be due to the 
fact that the most exposed volumes of OARs are not iden-
tical in the IMAT and CONF plans, since the dose of crit-
ical organs can be decreased with the IMAT technique, as 
is shown in Figure 4. 
The effect of BT technique on dose-volume param-
eters was also investigated in our study. Of note, all 
examined dosimetric parameters were statistically sig-
nificant. The most valuable plans were obtained using 
MOIS and IOIS, while MOIC resulted in worse dose-vol-
ume parameters, and the worst of all were NOIC plans. 
Conventional A-point-based (NOIC) plans often resulted 
in an overdosage of the HR-CTV (D90 88.7 vs. 82.2 Gy) 
compared to MOIC plans, but with higher doses to 
OARs. Paul et al. demonstrated that the dosimetric ad-
vantages of volume-based intracavitary planning pro-
duced more conformal plans than point-A-based plans. 
Volume-based plans resulted in a 6-12% reduction in 
the total dose to 2 cc of the OARs as well as an 8-37% 
reduction per BT fraction compared to point-A-based 
plans [37]. Previous studies have pointed out the strong 
correlation between local tumor control and D90 of HR-
CTV, with the best results above 85 Gy EQD2 [24]. In 
our case, 86% of the patients received at least this dose 
during the treatment (IMAT + MOIS BT). Patients who 
received EBRT boost and fewer fractions of BT are the 
‘underdosed’ cases, with a D90 of 79.2 Gy. However, for 
standard fractionation, D90 is 90.1 Gy (p = 0.0006). As the 
HR-CT is an integral part of the target volume in EBRT 
plans and the same constraint was used for IMAT and 
for CONF EBRT (95% of prescribed dose has to cover 
95% of the planning target volume homogeneously), no 
differences in the coverage of the HR-CTV were noted. 
The D2 OARs doses are the predictors of side effects. In 
86% of cases, rectal D2 remained below recommended 
tolerance level during the treatment, though this pro-
portion would have been only 43% using NOIC BT, and 
36% with NOIC BT and CONF EBRT. Moreover, the ef-
fect of the BT technique used is also larger than the EBRT 
technique. Van de Kamer et al. [16] showed that without 
EBRT boost, DVH parameter adding is a good approx-
imation method, but underestimates D90 by 2.8%. They 
used rigid image registration, and only 5 patients were 
investigated in this study. Our dose summation method 
showed that UDC overestimates D2 of bladder, rectum, 
and sigmoid in both EBRT techniques. The maximal de-
viation was 22 Gy (D2(r)). There was no difference be-
tween plans with or without EBRT boost, but there were 
only 8 cases of the former. 
Overall treatment time (OTT) is another influential 
factor of tumor control; 85 Gy should be delivered to HR-
CTV within 50 days [23]. At our Institute, it takes 61 days 
(on average), and we are planning to introduce OTT fac-
tor into our dose summation technique. 
This study is the starting point of the development 
of an algorithm for the summation of EBRT and BT bi-
ologically effective doses, which uses an artificial intel-
ligence-based DIR algorithm to match the critical ana-
tomical structures in the two radiotherapy modalities. 
Further investigations are needed to review whether 
our method better predicts toxicity than the recent UDC 
method. 
Conclusions 
A comparison between interstitial IGABT and IMAT 
versus conventional treatment techniques in the treat-
ment of cervical cancer using our biological dose sum-
mation method shows that interstitial optimized BT 
plans resulted in a significantly higher dose coverage to 
the HR-CTV and lower doses to the OARs, while IMAT 
decreases the rectal dose. UDC overestimates the OARs 
doses compared to a manual definition of D2 in the EBRT 
plans. 
Fig. 4. The most exposed 2 cc of bladder (yellow), rectum 
(brown), and sigmoid (orange) from BT in a sagittal CT 
slice in an intensity-modulated arc therapy plan. Red line: 
100%; yellow: 95% isodose line 
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